drugset / Trial / NCT07324408

Multiple Ascending Dose Study of NH102 in Healthy Subjects

NCT07324408

Phase 1 Completed 40 enrolled Jiangsu Nhwa Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of NH102 when administered as multiple oral dose at escalating dose levels in healthy participants.

Timeline

Start
2022-03-10
Primary completion
2023-04-10
Completion
2023-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject NH102 Unknown 3 mg Oral
Subject NH102 Unknown 10 mg Oral
Subject NH102 Unknown 15 mg Oral
Subject NH102 Unknown 20 mg Oral

Indications